NCT00609934View on ClinicalTrials.gov

Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Sorafenib

Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84

RADIATION

external beam radiotherapy

3000cGy in 10 fractions

Trial Locations (1)

M5G2M9

Princess Margaret Hosptial, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT00609934 - Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | Biotech Hunter | Biotech Hunter